- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
PhRMA recommends patent protection
The Office of the U.S. Trade Representatives released its annual report on the adequacy and effectiveness of intellectual-property protection in countries trading with the United States.
The Office of the U.S. Trade Representatives released its annual report on the adequacy and effectiveness of intellectual-property protection in countries trading with the United States.
The 1997 Special 301 Annual Review cited several countries for failing to adequately protect pharmaceutical intellectual property. Five - Argentina, Ecuador, Egypt, India and Turkey - were designated "Priority Watch" countries, and a special review was scheduled to assess Turkey's progress in improving patent protection.
"Without effective intellectual-property protection, there would be no innovative medicines," said Harvey E. Bale Jr., senior vice president of international affairs for Pharmaceutical Research and Manufacturers of America. PhRMA considers patents to be the lifeblood of its industry.
PhRMA asked that the government designate Argentina and India "Priority Foreign Countries" in order to expedite resolution of patent protection problems in those countries. Both are centers of regional and global patent piracy, according to PhRMA.
Other countries put on the "Watch" list for deficiencies related to pharmaceuticals include Australia, Chile, Columbia, Costa Rica, Israel, Jordan, Korea, Kuwait, Oman, Pakistan, Peru and the United Arab Emirates. The review also noted problems in Cyprus, Qatar and Romania.
"This report should prompt countries cited for deficiencies to improve their protection of intellectual property," Bale said.
"This will not only help them meet international standards, it will also benefit the people of those countries by making more innovative medicines available and by attracting investment," according to Bale. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
